Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 5, 2014, Pages 589-590

  Kitley, Joanna ^a   Leite, M Isabel ^a   Elsone, Liene ^b   Jacob, Anu ^b   Palace, Jackie ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; AQUAPORIN 4 ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

CLINICAL TRIAL (TOPIC); DISEASE DURATION; DRUG EFFICACY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MYELOOPTIC NEUROPATHY; ONSET AGE; PRIORITY JOURNAL; RELAPSE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION;

MULTIPLE SCLEROSIS; MYELOPATHY; NEUROIMMUNOLOGY;

DISEASE-FREE SURVIVAL; HUMANS; NEUROMYELITIS OPTICA; RECURRENCE; TIME FACTORS;

EID: 84898646091     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-306541     Document Type: Letter

References (5)

1. Collongues N, Marignier R, Zéphir H, et al. High-risk syndrome for neuromyelitis optica: a descriptive and comparative study. Mult Scler 2011;17:720-4.
2. Oh J, Levy M. Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int 2012:460825.
3. Palace J, Leite MI, Jacob A. A practical guide to the treatment of neuromyelitis optica. Pract Neurol 2012;12:209-14.
4. Tradtrantip L, Zhang H, Saadoun S, et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 2012;71:314-22.
5. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012;135:1834-49.